Landmark BioVentures AG

We’re kicking off our New York meetings tour with a presentation at #BioFuture2024 this morning showcasing CARLA Biotherapeutics, a Landmark BioVentures nexus company. If you’re in the city and want to connect to learn more about our integrated and agile biotech hub-and-spoke business model, let’s connect! Zaki Sellam Gary Brandam Mehdi Chelbi Josh Pan, PhD Dr Jacques-Alain Bauer Samson Fung

Duhn Therapeutics is officially launching with innovative technology from OM Pharma to advance lipid-based cancer immunotherapies for solid cancers associated or resulting from chronic non-resolved immunosuppressive inflammation. We’re extremely excited to welcome our 6th startup into the nexus as an integrated and agile biotech hub-and-spoke company. We would like to thank OM Pharma for its trust and collaborative mindset. Learn more at https://lnkd.in/gjTw-TKJ Zaki Sellam, Dr Jacques-Alain Bauer, Mehdi Chelbi, Samson Fung, Josh Pan, PhD, Etienne Jornod, Roch Ogier, Riccardo Nisato, Sara Webber DECA-BFC Région Bourgogne-Franche-Comté Bpifrance francois ghiringhelli Catherine Paul Université de Bourgogne

We’re looking forward to #BioFuture2024 where we’ll be presenting and highlighting the great work from CARLA Biotherapeutics developing CAR-T cell-based immunotherapies for a broad range of diseases initially targeting hematological malignancies and solid tumors Carla Biotherapeutics is a Landmark BioVentures nexus company spun out from Université de Franche-Comté and the EFS. We’ll be in New York 10/28-10/31, connect with us and let’s find a time to meet! Maxime FREDON, Francine Garnache Ottou, Olivier Adotevi, Fanny Delettre Zaki Sellam Mehdi Chelbi

Congratulations Mohamed Haitham Ayad and the entire SPIMA team! We are very excited to continue advancing this innovative science and lead therapy and welcome you formally (and publicly) into our nexus! Zaki Sellam Gary Brandam Mehdi Chelbi Dr Jacques-Alain Bauer Samson Fung

Today, our CEO, Zaki Sellam, and Executive Chair of Roca Therapeutics presented on Roca's first-in-class small molecule topical therapy for ocular diseases. The first indication addresses aggressive retinopathies with no available treatment options today. Thank you UBS for the invitation to present Roca Therapeutics, a Landmark BioVentures company, today. We continue to advance our IND-stage candidates into the clinic with the potential to treat orphan and aggressive retinopathies

In collaboration with SATT AxLR, we are excited to announce the launch of SPIMA Therapeutics, a pioneering preclinical-stage company developing #innovative peptide-based #immunotherapies for difficult-to-reach targets, especially protein-protein interactions. As co-founders, we officially welcome our 5th startup to our nexus of companies within our integrated and agile biotech hub-and-spoke business model. Learn more at https://lnkd.in/g7RrpHHX Mohamed Haitham Ayad, Zaki Sellam, Gary Brandam, Dr Jacques-Alain Bauer, Mehdi Chelbi, Samson Fung, Josh Pan, PhD

We are attending the SACHS – 24th Annual Biotech in Europe Forum on the 25th - 26th of September. Our CEO Zaki Sellam, COO Gary Brandam and CVO Mehdi Chelbi will be attending the event. Join us to learn more about our investment opportunities and the latest developments of LBV and our nexus our start-up Biotechs! See you there!

📣 CARLA Biotherapeutics , one of start-up of Landmark BioVentures AG nexus , is currently developing a promising 3rd generation CAR T cell therapy against  #BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)  outperforming other anti CD123 CAR T Cell therapies. Latest results, its sophisticated and tailored design, are described in the manuscript published in Cancer Immunology Research more informations (see the manuscript below 👇 ). CARLA Biotherapeutics is a spin off from EFS Université de Franche-Comté and INSERM UMR Right focused on the development of first-in-class adoptive cell therapies tailored to treat diseases with high unmet medical need with a first focus on aggressive life-threatening cancers including haematological malignancies and solid tumors. Congrats to the whole team Maxime FREDON Elodie BÔLE-RICHARD Francine Garnache Ottou Olivier Adotevi UMR Right Région Bourgogne-Franche-Comté DECA-BFC https://lnkd.in/dTUXWK9Y

Interview of Maeva Dufies CSO/COO of Roca Therapeutics a company of Landmark BioVentures AG nexus. The interview held in French highlights the future exciting developments of Roca Therapeutics pipeline of programs in #ophtalmology and in #oncology as well as the essential role of Bpifrance in support of Roca Therapeutics R&D programs. In the Nexus of Landmark BioVentures AG two companies are i-Lab laureates - iLab is one of the most supportive and prestigious French awards for innovative start-ups Biotech companies - A great recognition of the science and the work carried by the start-ups of our nexus. Thank you Bpifrance and congratulations to Maeva Dufies and the whole team for such achievements !

📣 Elikya Therapeutics, a company of the Landmark BioVentures AG nexus, and spinoff from the Gustave Roussy institute and Université Paris-Saclay showcased its ground-breaking new technology focusing on toxic payloads for Antibody Drug Conjugates (#ADCs) at the prestigious pitch studio of Gustave Roussy during Viva Technology 2024, the biggest tech and healthtech event in Europe. Elikya Therapeutics is focused on the development of next Generation of ADCs using its First-in-Class toxic payload, with a unique mode of able to address tumor and its microenvironment in parallel, and with a long-standing memory immune response. Elikya's unique approach focuses also on the development of Precision Conjugates: considering that new ADCs shall be designed on the comprehensive mechanistic properties of the payload (payload centric design) Elikya Therapeutics Quest for health Gary Brandam Zaki Sellam Bpifrance Dr Jacques-Alain Bauer Mouad Alami sebastien apcher